Please ensure Javascript is enabled for purposes of website accessibility

RegeneRx patents extended

The U.S. Patent and Trademark Office has extended three patents held by RegeneRx Biopharmaceuticals Inc., of Rockville, the company announced. The extensions were based on new rules contained in the America Invents Act Technical Corrections Act. A patent for a method of treating tissue deterioration received about a 4½-year extension, and patents dealing with treating extracellular matrix buildup in the heart and freeze-dried peptides each were extended more than 3½ years.